KRYSTEXXA development and treatment failure gout to be presented

Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that five abstracts relating to KRYSTEXXA(TM) (pegloticase) development and treatment failure gout will be presented at the 2009 ACR/ARHP Annual Scientific Meeting taking place in Philadelphia from October 16-21, 2009. The posters will be presented during the "Treatment and Outcome" session on October 19, 2009 and include:

• Chronic Use of Pegloticase: Safety and Efficacy Update (Abstract # 1113) - October 19, 2009 at 9:00 a.m. Eastern Time

• First Application of Computer-Assisted Analysis of Digital Photographs for Assessing Tophus Response: Phase 3 Studies of Pegloticase in Treatment Failure Gout (Abstract # 1111) - October 19, 2009 at 9:00 a.m. Eastern Time

• Improvement in Health-Related Quality of Life (HRQOL) in Patients with Treatment Failure Gout (TFG) Treated with Pegloticase Measured by SF-6D Derived Utility (Abstract # 1101) - October 19, 2009 at 9:00 a.m. Eastern Time

• Routine Serum Uric Acid (SUA) Monitoring Predicts Antibody-Mediated Loss of Response and Infusion Reaction Risk during Pegloticase Therapy (Abstract # 1104) - October 19, 2009 at 9:00 a.m. Eastern Time

• The Costs of Treatment Failure Gout: A Claims-Based Analysis (Abstract # 1112) - October 19, 2009 at 9:00 a.m. Eastern Time